Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles

PurposeThe aim of this study was to investigate the depth-dependent intradermal immunogenicity of inactivated polio vaccine (IPV) delivered by depth-controlled microinjections via hollow microneedles (HMN) and to investigate antibody response enhancing effects of IPV immunization adjuvanted with CpG oligodeoxynucleotide 1826 (CpG) or cholera toxin (CT).MethodsA novel applicator for HMN was designed to permit depth- and volume-controlled microinjections. The applicator was used to immunize rats intradermally with monovalent IPV serotype 1 (IPV1) at injection depths ranging from 50 to 550 μm, or at 400 μm for CpG and CT adjuvanted immunization, which were compared to intramuscular immunization.ResultsThe applicator allowed accurate microinjections into rat skin at predetermined injection depths (50–900 μm), -volumes (1–100 μL) and -rates (up to 60 μL/min) with minimal volume loss (±1–2%). HMN-mediated intradermal immunization resulted in similar IgG and virus-neutralizing antibody titers as conventional intramuscular immunization. No differences in IgG titers were observed as function of injection depth, however IgG titers were significantly increased in the CpG and CT adjuvanted groups (7-fold).ConclusionIntradermal immunogenicity of IPV1 was not affected by injection depth. CpG and CT were potent adjuvants for both intradermal and intramuscular immunization, allowing effective vaccination upon a minimally-invasive single intradermal microinjection by HMN.

[1]  Hiromasa Okayasu,et al.  Affordable inactivated poliovirus vaccine: strategies and progress. , 2014, The Journal of infectious diseases.

[2]  Rong-cheng Li,et al.  Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. , 2011, Vaccine.

[3]  M. Pallansch,et al.  Vaccine-derived polioviruses and the endgame strategy for global polio eradication. , 2005, Annual review of microbiology.

[4]  E. Hohmann,et al.  Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant. , 2013, Vaccine.

[5]  N. Roxhed,et al.  Membrane-sealed hollow microneedles and related administration schemes for transdermal drug delivery , 2008, Biomedical microdevices.

[6]  R. Sutter,et al.  Priming after a fractional dose of inactivated poliovirus vaccine. , 2013, The New England journal of medicine.

[7]  H. Beydoun,et al.  Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. , 2015, The Journal of infectious diseases.

[8]  T. Vedvick,et al.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. , 2013, Vaccine.

[9]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[10]  Jean‐Pierre Amorij,et al.  Alternative delivery of a thermostable inactivated polio vaccine. , 2015, Vaccine.

[11]  M. Pichichero,et al.  Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial , 2009, Pediatrics.

[12]  K. Chumakov,et al.  Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study. , 2015, The Journal of infectious diseases.

[13]  Wijaya Martanto,et al.  Microinfusion Using Hollow Microneedles , 2006, Pharmaceutical Research.

[14]  E. Curry,et al.  Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants , 2001, The Pediatric infectious disease journal.

[15]  Koen van der Maaden,et al.  Layer-by-Layer Assembly of Inactivated Poliovirus and N-Trimethyl Chitosan on pH-Sensitive Microneedles for Dermal Vaccination. , 2015, Langmuir : the ACS journal of surfaces and colloids.

[16]  C. Boog,et al.  Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. , 2013, Vaccine.

[17]  S. Troy,et al.  Adjuvants and inactivated polio vaccine: a systematic review. , 2012, Vaccine.

[18]  R. Sutter,et al.  Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. , 2015, Vaccine.

[19]  P. Andersen,et al.  Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01 , 2014, PloS one.

[20]  R. Sutter,et al.  Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. , 2010, The Journal of infectious diseases.

[21]  J. Salk,et al.  Standardization of poliovirus neutralizing antibody tests. , 1984, Reviews of infectious diseases.

[22]  M. Pallansch,et al.  Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. , 2012, The Lancet. Infectious diseases.

[23]  M. Pallansch,et al.  Fractional doses of inactivated poliovirus vaccine in Oman. , 2010, The New England journal of medicine.

[24]  D. Liepmann,et al.  In vivo evaluation of a microneedle-based miniature syringe for intradermal drug delivery , 2009, Biomedical microdevices.

[25]  Koen van der Maaden,et al.  Microneedle technologies for (trans)dermal drug and vaccine delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[26]  M. Pallansch,et al.  Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. , 2015, Vaccine.

[27]  J. Bouwstra,et al.  Animal models for cutaneous vaccine delivery. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  Jung-Hwan Park,et al.  Microneedles for drug and vaccine delivery. , 2012, Advanced drug delivery reviews.

[29]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[30]  Scott A. Burton,et al.  Rapid Intradermal Delivery of Liquid Formulations Using a Hollow Microstructured Array , 2010, Pharmaceutical Research.

[31]  D. Klinman,et al.  Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. , 2014, Vaccine.

[32]  Thomas Hankemeier,et al.  Novel Hollow Microneedle Technology for Depth-Controlled Microinjection-Mediated Dermal Vaccination: A Study with Polio Vaccine in Rats , 2014, Pharmaceutical Research.

[33]  Yanwen Liang,et al.  CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. , 2009, Vaccine.

[34]  B. Combadière,et al.  Transcutaneous and intradermal vaccination , 2011, Human vaccines.

[35]  Mark R Prausnitz,et al.  Precise microinjection into skin using hollow microneedles. , 2006, The Journal of investigative dermatology.

[36]  Göran Stemme,et al.  Painless Drug Delivery Through Microneedle-Based Transdermal Patches Featuring Active Infusion , 2008, IEEE Transactions on Biomedical Engineering.

[37]  M. Prausnitz,et al.  Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. , 2015, Vaccine.

[38]  M. Bonnet,et al.  Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[39]  W. Weldon,et al.  The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. , 2015, Vaccine.